A PHASE 3, DOUBLE-BLIND, RANDOMIZED, ADAPTIVE DESIGN STUDY TO EVALUATE THE
EFFICACY AND SAFETY OF RAVULIZUMAB IN ADULT PARTICIPANTS WITH IMMUNOGLOBULIN A
NEPHROPATHY (IGAN)
- Registry ID
- ALXN1210-IGAN-320
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- ALEXION PHARMACEUTICALS INC
- Start date
- 2026-06-30
- Last update
- 2024-03-12
Conditions
- IMMUNOGLOBULIN A
NEPHROPATHY
View on source registry